Samsung Pharm (001360) - Total Liabilities

Latest as of September 2025: ₩44.04 Billion KRW ≈ $29.85 Million USD

Based on the latest financial reports, Samsung Pharm (001360) has total liabilities worth ₩44.04 Billion KRW (≈ $29.85 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 001360 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

Samsung Pharm - Total Liabilities Trend (2012–2024)

This chart illustrates how Samsung Pharm's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Samsung Pharm asset portfolio.

Samsung Pharm Competitors by Total Liabilities

The table below lists competitors of Samsung Pharm ranked by their total liabilities.

Company	Country	Total Liabilities
Delta Djakarta Tbk JK:DLTA	Indonesia	Rp285.36 Billion
iFabric Corp TO:IFA	Canada	CA$22.29 Million
Europap Tezol Kagit Sanayi Ve Ticaret AS IS:TEZOL	Turkey	TL1.56 Billion
Invictus Energy Ltd AU:IVZ	Australia	AU$1.45 Million
NEOOTO Co. Ltd KQ:212560	Korea	₩70.52 Billion
Advenica AB ST:ADVE	Sweden	Skr69.09 Million
Big River Industries Ltd AU:BRI	Australia	AU$145.90 Million
U&I Corporation KQ:056090	Korea	₩31.20 Billion

Liability Composition Analysis (2012–2024)

This chart breaks down Samsung Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Samsung Pharm net asset quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.54	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.24	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.20	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Samsung Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Samsung Pharm (2012–2024)

The table below shows the annual total liabilities of Samsung Pharm from 2012 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩22.60 Billion ≈ $15.31 Million	+42.17%
2023-12-31	₩15.89 Billion ≈ $10.77 Million	+3.72%
2022-12-31	₩15.32 Billion ≈ $10.39 Million	-15.73%
2021-12-31	₩18.19 Billion ≈ $12.32 Million	-67.99%
2020-12-31	₩56.81 Billion ≈ $38.50 Million	+121.03%
2019-12-31	₩25.70 Billion ≈ $17.42 Million	-11.32%
2018-12-31	₩28.98 Billion ≈ $19.64 Million	-51.95%
2017-12-31	₩60.33 Billion ≈ $40.88 Million	+7.90%
2016-12-31	₩55.91 Billion ≈ $37.89 Million	-33.43%
2015-12-31	₩83.98 Billion ≈ $56.91 Million	+146.17%
2014-12-31	₩34.12 Billion ≈ $23.12 Million	-50.05%
2012-12-31	₩68.31 Billion ≈ $46.29 Million	--

About Samsung Pharm

KO:001360 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$83.37 Million

₩123.02 Billion KRW

Market Cap Rank

#19950 Global

#1046 in Korea

Share Price

₩1307.00

Change (1 day)

-0.08%

52-Week Range

₩1180.00 - ₩2210.00

All Time High

₩12289.83